×
LendingTree reported third-quarter 2026 revenue of $343.6 million , up 11.6% year over year and above analyst consensus estimates of roughly $329.6 million. The company posted a GAAP net loss of $72.4 million , or $5.15 per diluted share, driven primarily by a $98.8 million non-cash goodwill impairment charge in its Home and Consumer segments.
Third quarter 2026 total revenue rose 31% year over year to $480.3 million, up from $365.4 million in the prior-year period. The company posted a GAAP (Generally Accepted Accounting Principles) net loss of $81.6 million, a net loss margin of 17%, reflecting one-time go-private costs.
CorVel reported second quarter fiscal 2027 revenue of $267 million , up 11% from $240 million in the same quarter a year earlier. Diluted earnings per share rose 24% to $0.67 , compared with $0.54 in the prior-year period.
Ethos Technologies reported third-quarter fiscal 2026 revenue of $235.2 million , up 151% year over year and well above the consensus estimate of $169.0 million. Non-GAAP earnings per share (EPS, a company's profit divided by its shares outstanding) came in at $0.49 , beating the consensus estimate of $0.35.
SelectQuote operates a technology-enabled, direct-to-consumer platform that distributes senior (Medicare) insurance, life insurance, and healthcare services, including its SelectRx pharmacy. Over the trailing 30 days, SLQT shares have been roughly flat, trading near $0.41, after dipping into the low $0.30s in mid-October before recovering.
XHG slid from a $4.07 prior close to $3.68, a -9.58% decline, during Monday's regular session. No verified news or fundamental catalyst found. The drop is likely profit-taking after a parabolic October surge from roughly $1.88 to $4.07, consistent with speculative micro-cap trading in a stock that routinely swings about 10% a day.
ABBV (AbbVie) trades near record highs after a strong quarter, supported by double-digit revenue growth, a raised outlook, and a dividend increase. ADUS (Addus HomeCare) reached a fresh 52-week high, with acquisition-driven expansion and steady home-care demand as key catalysts.
Structural transformation underway: Following its January 2026 ticker change to EZRA, the company is repositioning around the EZRA International Group and "Scale51" initiative, targeting controlling stakes in cybersecurity, AI, data analytics, FinTech, InsurTech, and MedTech ventures. Dual-engine strategy: Cash-generating insurance operations are intended to fund early-stage technology and life sciences investments, a model that pairs recurring cash flow with higher-risk growth optionality.
The $3.00 target used here is not an analyst consensus; it is a fallback objective drawn from public discussion and technical price levels, because EZRA lacks credible, current analyst price targets. The stock recently traded near $2.28, meaning the $3.00 level implies roughly a 32% move — a substantial gap for a nano-cap with heavy dilution and ongoing losses.
EZRA shares declined roughly 10% over the trailing 30 days, falling from about $2.28 at the close of September 30, 2026, to $2.05 at the close of October 30, 2026. The pullback came despite a string of strategic announcements, including the full retirement of the company's term debt and a letter of intent to acquire a GPU cloud provider.
Ryan Specialty reported third quarter 2026 total revenue of $790.0 million, up 4.7% from $754.6 million a year earlier, though slightly below consensus estimates. Adjusted (non-GAAP) diluted earnings per share came in at $0.51, beating the analyst consensus of $0.49 by $0.02.
Erie Indemnity reported third quarter 2026 net income of $182.0 million , or $3.48 per diluted share , compared with $182.9 million, or $3.50 per diluted share, in the prior-year quarter. Diluted earnings per share (EPS) of $3.48 beat the consensus analyst estimate of $3.41 by $0.07.
WTW reported third-quarter 2026 revenue of $2.46 billion , up 8% from $2.29 billion a year earlier, while organic revenue rose 4%. Adjusted diluted earnings per share (EPS) came in at $3.63 , an 18% increase over the prior-year quarter and modestly above consensus estimates of roughly $3.60.
Arthur J. Gallagher & Co. reported third quarter 2026 revenue of roughly $3.98 billion , up about 18% year over year but modestly below the roughly $4.00 billion consensus estimate. Adjusted earnings per share (EPS, or profit divided by shares outstanding) came in at $3.00 , slightly above the consensus estimate of $2.99 and up from $2.31 a year earlier.
AIFU shares traded near $9.16 in late October, approximately 15.4% below the $10.83 closing level recorded about 30 days earlier. The pullback extends a longer decline: over the trailing quarter, the stock has fallen from roughly $32.50, a drop of about 72%.
CLOV is a fast-growing Medicare Advantage and physician-enablement technology company, while WTW is a diversified global advisory, broking, and solutions firm with steadier, more mature economics. Recent momentum clearly favors CLOV : it is riding rapid membership growth, a top-quality plan rating, and a shift toward GAAP profitability, whereas WTW has lagged the broader market in 2026.
Total revenue rose 3% year over year to $4.101 billion , led by 6% organic revenue growth across the business. Adjusted earnings per share (EPS) climbed 10% to $3.36 , edging above Wall Street consensus estimates near $3.30–$3.34.
RYAN is down -5.49% during regular trading, near $42.03 versus the prior close of $44.47. Primary catalyst: softening commercial property pricing (rate declines of 25%–35%) is pressuring organic growth and margins ahead of Q3 results.
Total revenues rose 7.4% year over year to $1.725 billion, driven primarily by acquisitions rather than underlying expansion. Organic revenue growth slowed to just 1.2% in the quarter, or 1.5% when including contingent commissions.
Brown & Brown (BRO) climbed roughly 20% over the trailing 30 days, from a close of $60.82 on September 25 to $72.97 on October 23. The rebound followed a late-September low near $60 and was driven by strength across insurance-brokerage peers plus a wave of positive analyst actions.